The A$28-per-share offer, which values Sirtex at A$1.59 billion (about $1.28 billion), is slated to close in late May, Palo Alto, Calif.-based Varian said. It’s part of a bid to broaden that company’s oncology portfolio.
Sirtex makes the SIR-Sphere Y-90, a resin microsphere designed to deliver radiation therapy to liver cancers. The company put up sales of about $189.4 million (A$234.0 million) during the fiscal year ended June 30, 2017 and employs about 300 workers.
“This acquisition is the latest step in Varian’s long-term strategy to become a global leader in multi-disciplinary integrated cancer care solutions,” Varian CEO Dow Wilson said in prepared remarks. “The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community. Our companies share a common vision of a world without fear of cancer, and we look forward to completing this acquisition and positively impacting more patients’ lives around the world.”
Varian said it plans to fund the deal with cash and debt. It’s expected to be accretive to earnings per share during its first full fiscal year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.